PDRN CarePDRN for Wound Healing in Diabetic Models: A Preclinical Study (2008)
Dr. Sarah Chen
PhD, Molecular Biology
Key Findings
PDRN-treated diabetic mice showed significantly faster wound closure compared to saline-treated controls, with complete healing achieved 5-7 days earlier [1].
VEGF expression was markedly increased in PDRN-treated wounds, restoring angiogenic capacity to near-normal levels despite the diabetic impairment [1,2].
The wound-healing effects of PDRN were blocked by the selective A2A receptor antagonist DMPX, confirming that the therapeutic mechanism is mediated through adenosine A2A receptor activation [1].
Key Findings
- PDRN-treated diabetic mice showed significantly faster wound closure compared to saline-treated controls, with complete healing achieved 5-7 days earlier [1].
- VEGF expression was markedly increased in PDRN-treated wounds, restoring angiogenic capacity to near-normal levels despite the diabetic impairment [1][2].
- The wound-healing effects of PDRN were blocked by the selective A2A receptor antagonist DMPX, confirming that the therapeutic mechanism is mediated through adenosine A2A receptor activation [1].
Abstract
This preclinical study by Galeano et al. investigated the wound-healing properties of PDRN in genetically diabetic (db/db) mice, a well-established model of impaired wound healing [1]. Diabetic wounds are characterized by reduced growth factor expression, impaired angiogenesis, and persistent inflammation β closely mirroring the pathology of diabetic foot ulcers in humans [1][5]. PDRN was administered via local injection at the wound site, and healing was assessed by wound area reduction, histological analysis, and molecular markers [1].
Methods
Full-thickness excisional wounds (1 cm diameter) were created on the dorsum of db/db diabetic mice and wild-type controls [1]. Animals received either PDRN (8 mg/kg, local injection every other day) or saline vehicle for the duration of the study [1]. A subset of PDRN-treated animals also received DMPX (3,7-dimethyl-1-propargylxanthine), a selective A2A receptor antagonist, to test the receptor-dependency of the observed effects [1].
Primary endpoints included wound area (planimetric measurement), time to complete closure, VEGF protein expression (Western blot), capillary density (histological quantification), and inflammatory markers [1].
Results
PDRN-treated diabetic mice demonstrated significantly accelerated wound healing compared to saline-treated diabetic controls [1]. Wound area at day 14 was reduced by approximately 45% in the PDRN group versus controls [1]. Complete wound closure occurred by day 21 in PDRN-treated animals, compared to day 28 in controls [1].
Mechanistically, PDRN treatment produced [1][2]:
- VEGF upregulation β PDRN-treated wounds showed a 3.5-fold increase in VEGF protein expression versus diabetic controls, restoring levels to near-wild-type values [1]
- Increased capillary density β Histological analysis revealed significantly more capillaries per high-power field in PDRN-treated wounds [1]
- Reduced inflammatory infiltrate β PDRN-treated wounds showed less persistent neutrophilic infiltration and earlier transition to the proliferative phase [1][4]
Critically, co-administration of the A2A antagonist DMPX abolished all PDRN-mediated improvements in wound healing, VEGF expression, and angiogenesis [1]. This pharmacological reversal provided strong evidence that PDRN's therapeutic effects are specifically mediated through adenosine A2A receptor activation [1][2].
Significance
This study is considered a landmark in PDRN research for several reasons [2][3]:
- Mechanism confirmation β It provided the first clear demonstration that PDRN's wound-healing effects are specifically A2A receptor-dependent, establishing the mechanistic foundation for all subsequent PDRN research [1][2]
- Impaired healing model β By demonstrating efficacy in a diabetic model with inherently compromised healing, the study showed that PDRN can overcome pathological barriers to repair, not just accelerate normal healing [1][3]
- Clinical translation β The findings directly supported the development of PDRN for clinical wound healing and subsequently for aesthetic applications where tissue regeneration is the therapeutic goal [2][3]
Conclusion
This study established that PDRN stimulates angiogenesis and accelerates wound closure in diabetic models through A2A receptor activation [1]. The restoration of VEGF expression in growth factor-deficient diabetic tissue provided a compelling rationale for PDRN's use in any condition where impaired tissue repair or regeneration is present β including the photoaged and chronically inflamed skin targeted by aesthetic PDRN treatments [2][3].
References
- [1]Galeano M, Bitto A, Altavilla D, Minutoli L, Polito F, CalΓ² M, Lo Cascio P, Stagno d'Alcontres F, Squadrito F. Polydeoxyribonucleotide stimulates angiogenesis and wound healing in the genetically diabetic mouse. Wound Repair and Regeneration. 2008;16(2):208-217. doi:10.1111/j.1524-475X.2008.00361.x
- [2]Squadrito F, Bitto A, Irrera N, Pizzino G, Pallio G, Minutoli L, Altavilla D. Pharmacological Activity and Clinical Use of PDRN. Current Pharmaceutical Design. 2017;23(27):3948-3957. doi:10.2174/1381612823666170516153716
- [3]Veronesi F, Dallari D, Sabbioni G, Carubbi C, Martini L, Fini M. Polydeoxyribonucleotides (PDRNs): From Physical Chemistry to Biological Activities and Clinical Applications. International Journal of Molecular Sciences. 2017;18(9):1927. doi:10.3390/ijms18091927
- [4]Bitto A, Polito F, Irrera N, et al.. Polydeoxyribonucleotide reduces cytokine production and the severity of collagen-induced arthritis by stimulation of adenosine A2A receptor. Arthritis Research & Therapy. 2011;13(1):R28. doi:10.1186/ar3254
- [5]Barrientos S, Stojadinovic O, Golinko MS, Brem H, Tomic-Canic M. Growth factors and cytokines in wound healing. Wound Repair and Regeneration. 2008;16(5):585-601. doi:10.1111/j.1524-475X.2008.00410.x